Correction to previous pressrelease: Active Biotech updates its clinical strategy and projected milestones
Correction: All information was not included in previous pressrelease.
PRESS RELEASE, Lund Sweden, November 24, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI)
Active Biotech AB (publ) (ticker: ACTI) today announced updates of its fully owned projects tasquinimod and laquinimod, as well the project naptumomab, developed in partnership with NeoTX Therapeutics. Investors, analysts and media are invited to today’s virtual Capital Markets Day where the current status and future developments of the company’s clinical portfolio and its future strategy will be highlighted.
In August, the first patient was dosed in the phase 1b/2a clinical study of tasquinimod for treatment of relapsed or refractory multiple myeloma. The study, which is planned to recruit up to 54 patients, will establish a maximum tolerated dose of tasquinimod as single agent and then investigate tasquinimod in combination with a standard multiple myeloma oral regimen of ixazomib, lenalidomide, and dexamethasone (IRd).
For both single agent tasquinimod and the combination of tasquinimod and IRd, exploratory expansion cohorts will be enrolled to characterize the anti-myeloma activity of each regimen.
Pre-clinical data support the use of laquinimod for treatment of the eye disorders uveitis and wet AMD. Our focus for the clinical development will be non-infectious non-anterior uveitis, an orphan disease, and a serious, sight-threatening condition. Our plan for starting clinical development in uveitis, is to use the capsule formulation already developed, and initiate a phase 2 proof-of-principle study in H2 2021.
We have also, together with Leukocare AG, developed a topical eye formulation of laquinimod. Entry into clinical efficacy studies for this new formulation, requires further pre-clinical tests and a phase 1 clinical trial which we are working towards initiating also.
The phase 1b/2 study with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced solid tumors aims to establish the maximum tolerated dose of the combination before advancing to a larger expansion phase in various indications. The study is enrolling according to plan and we look forward to reviewing results from the dose escalation phase of this trial during the first half of 2021. NeoTX plan to expand the clinical program of the naptumomab combination with durvalumab across indications with focus on so called “cold tumors” with poor response to checkpoint inhibition alone, as well as further evaluate combination strategies such as the combination with docetaxel.
Projected future milestones:
• Safety readout and start of MTD (maximum tolerated dose) cohort of phase 1b study
• Safety readout and MTD expansion for single agent tasquinimod
• Start of combination study with tasquinimod and IRd
• Start of oral Proof-of-principle phase 2 study
• Start of phase 1 topical eye formulation study
• Start of phase 2 study in ”cold tumors” in combination with durvalumab
• Start of phase 2 study in Non-Small Cell Lung Cancer in combination with docetaxel
• Safety readout of combination study with tasquinimod and IRd
• Readout of MTD cohort of the phase 1b study regarding safety and preliminary effect
• Preliminary response readout of single agent tasquinimod
• Start of expansion cohort of combination study
• Safety readout of phase 1 topical eye formulation study
• Start of phase 2b study of single agent tasquinimod
• Proof-of-principle readout of oral phase 2 study
• Readout of phase 2 studies ”cold tumors” in combination with durvalumab
• Readout phase 2 study in Non-Small Cell Lung Cancer in combination with docetaxel
“I am very pleased with the progress we have achieved across our development projects since our new research focus was announced earlier this year, and we have a busy schedule ahead of us in the next coming years. The proposed rights issue of SEK 75 million which we announced recently will be used for advancing our prioritized project activities,” said Active Biotech’s CEO Helén Tuvesson.
Capital Markets Day being held today (virtual)
Today, Active Biotech will host a virtual Capital Markets Day for investors, analysts and media. Presentations from Executive Management and international experts can be found on our Capital Markets Day site: www.activebiotech.com/en/capital-markets-day-2020/. There you also can follow the live-streamed Q&A webcast starting at 14:00 CET today.
You can send questions in advance or during the actual Q&A session via email
(email@example.com) or text message (+46703119960).
The live Q&A session will be held in English.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, firstname.lastname@example.org
Hans Kolam, CFO, +46 46 19 20 44, email@example.com
Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication November 24, 2020 at 08.00 CET.
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a Phase 1/2 clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase 1b/2a for treatment of multiple myeloma. Laquinimod is advancing to phase 2 for treatment of non-infectious uveitis during second half of 2021. Please visit www.activebiotech.com for more information.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Bavarian Nordic Reports Preliminary Financial Results for 202028.1.2021 13:19:50 CET | Press release
Revenue and EBITDA in line with guidance for 2020. Year-end cash position better than guided for 2020 COPENHAGEN, Denmark, January 28, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today reported preliminary, unaudited financial results for 2020 in line with or better than the Company’s most recent guidance. Revenue for the full year is expected at approximately DKK 1,852 million, comprised of DKK 1,082 million from combined sale of Rabipur/RabAvert and Encepur, DKK 704 million from US Government sale, including JYNNEOS revenue and contract work, and finally DKK 66 million from the milestone payment from Janssen (Ebola vaccine approval).The operating result (EBITDA) is expected at approximately DKK 740 million, including other operating income of DKK 628 million from the sale of Priority Review Voucher.Cash position at year-end was approximately DKK 1,670 million, excluding unutilized credit facilities of DKK 244 million. DKK millionFY 2020 Guidance originalFY 2020 Guidance update
Bavarian Nordic offentliggør foreløbige resultater for 202028.1.2021 13:19:50 CET | pressemeddelelse
Omsætning og EBITDA på linje med forventningerne til 2020. Likvider ved årets udgang var bedre end forventet. KØBENHAVN, Danmark, 28. januar 2021 – Bavarian Nordic A/S (OMX: BAVA) rapporterede i dag foreløbige, ureviderede finansielle resultater for 2020 på linje med, eller bedre end selskabets senest udmeldte forventninger. Omsætningen for helåret forventes at være ca. DKK 1.852 mio., bestående af DKK 1.082 mio. fra det kombinerede salg af Rabipur/RabAvert og Encepur, DKK 704 mio. fra salg til den amerikanske regering, inklusive omsætning fra JYNNEOS og kontraktarbejde, samt DKK 66 mio. fra milepælsbetalingen fra Janssen (godkendelse af ebolavaccinen).Resultatet af primær drift før afskrivninger og nedskrivninger (EBITDA) forventes at være ca. DKK 740 mio., inklusive andre driftsindtægter på DKK 628 mio. fra salget af Priority Review Voucher.Likvider ved årets udgang udgjorde ca. DKK 1.670 mio., eksklusive uudnyttede kreditfaciliteter på DKK 244 mio. DKK mio. 2020 forventet oprindelig
German University Hospital Orders Nexstim NBS System with NexSpeech28.1.2021 10:40:00 CET | Press release
Press release, Helsinki, 28 January 2021 at 11.40 am (EET) German University Hospital Orders Nexstim NBS System with NexSpeech Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a University Hospital in Germany has ordered a Nexstim NBS System with NexSpeech. The hospital is a new customer for Nexstim. The NBS System with NexSpeech will be used for neuroscientific research and diagnostics. Nexstim NBS System uses the unique SmartFocus® navigated transcranial magnetic stimulation (nTMS) technology which enables accurate and precise stimulation of the brain. SmartFocus® nTMS mapping conducted with NBS system is a non-invasive and accessible way of diagnosing the tumour’s or other lesion’s location. In addition to motor mapping, NBS System can be used also for locating language eloquent areas when used together with NexSpeech module. Mikko Karvinen, CEO of Nexstim, said: “I’m very happy to welcome this new hospital and its team to our SmartFocus® nTMS user communit
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS28.1.2021 10:10:00 CET | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-01-28Loan195Coupon1.00 %ISIN-codeSE0013546066Maturity2025-06-18 Tendered volume, SEK mln1,300 +/- 650 Volume offered, SEK mln4,250Volume bought, SEK mln1,300Number of bids9Number of accepted bids5Average yield0.040 %Lowest accepted yield0.038 %Highest yield0.044 %% accepted at lowest yield 57.14 Auction date2021-01-28Loan1590Coupon1.00 %ISIN-codeSE0012676690Maturity2025-09-03 Tendered volume, SEK mln1,500 +/- 750 Volume offered, SEK mln5,926Volume bought, SEK mln1,500Number of bids12Number of accepted bids3Average yield0.066 %Lowest accepted yield0.061 %Highest yield0.068 %% accepted at lowest yield 29.87 Auction date2021-01-28Loan146Coupon0.50 %ISIN-codeSE0013381571Maturity2025-06-11 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln4,500Volume bought, SEK mln800Number of bids12Number of accepted bids1Average yield0.073 %Lowest accepted yield0.073 %Highest yield0.073 %% accepted at lowest yield 100.00 Auc
Share Buyback Transaction Details January 21 – 27, 202128.1.2021 10:00:00 CET | Press release
Share Buyback Transaction Details January 21 – 27, 2021 January 28, 2021 - Wolters Kluwer today reports that it has repurchased 99,498 of its own ordinary shares in the period from January 21, 2021, up to and including January 27, 2021, for €6.9 million and at an average share price of €69.79. These repurchases are part of the share buyback program announced on October 30, 2020, under which we intend to repurchase shares for up to €50 million during the period starting January 4, 2021, up to and including February 22, 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 357,57525.069.91 For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Associati
Rockridge Intersects 2.5 g/t Au over 13.0m containing 9.6 g/t Au over 2.0m and Makes New Gold Discovery 250m West of Main Zone; Assays Pending for Two Additional Holes28.1.2021 09:30:00 CET | Press release
VANCOUVER, British Columbia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd.(TSX-V: ROCK)(OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge”) (the “Company”) is pleased to announce that it has completed a 2,965 metre diamond drilling program at its 100% owned Raney Gold Project located southwest of Timmins, Ontario, Canada (the “Raney Gold Project” or “Property”). A total of 11 drill holes were completed to evaluate the down plunge and strike extent of the Raney Gold Zone. Assays have been received for 9 of the 11 holes with gold mineralization intersected in all but two holes. Drill hole RN 20-13 returned 2.5 g/t Au over 13.0m from 133.0m to 146.0m including 3.41 g/t Au over 9.0m from 135.0m to 144.0m and including 9.6 g/t Au over 2.0m from 135.0m to 137.0m. Furthermore, exploratory drill hole RN 20-18 was a significant step out hole along strike 250m to the west of the main zone and returned 1.36 g/t Au over 9.0m from 141.0m to 150.0m including 2.1 g/t Au over 4.0m from 141.0m to
Vital Partners with Radboud University Medical Center to Deliver Next Generation VNA, a Data Orchestration Engine28.1.2021 09:00:00 CET | Press release
MINNETONKA, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vital, a Canon Group company, has been awarded a contract by Radboud University Medical Center of Nijmegen, Netherlands. This announcement was preceded by an extensive, production-ready proof of concept, in which Vital proved to be a reliable partner as it successfully integrated its Vendor Neutral Archive (VNA) solution with Radboud's existing architecture and workflow. With Vital's VNA connecting Radboud's data silos, Radboud was able to promote efficiency at all levels of care. Radboud now has the ability to free key information from proprietary software, having data readily available at faster rates. This helps support Radboud's goal of ensuring every patient always receives the best care, now and in the future. “We needed a scalable vendor-agnostic solution that could consistently connect data within our systems.” says Laurens de Grootwe, a Lead Product Owner in Information Management at Radboud UMC. “We found that solution with